Multiple Sclerosis. Demyelinating diseases of the central nervous system
Conditions
Interventions
BMP oral capsules, each containes 500 mg active ingredient.
Treatment - Drugs
BMP oral capsules, each containes 500 mg active ingredient
Sponsors
Iran Rheumatism Center
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age between 18 and 50 Multiple sclerosis diagnosis by Mac Donald criteria EDSS more than six Signing informed consent Exclusion criteria: Sever hepatic/ Renal or cardiac diease Sever psychological disorders Adminstration of IVIG, Mitoxantrone, Plasmapheresis or immunosupressive drug since three months before Pegnancy or intention to pregnancy
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in MRI (Magnetic Resonance Imaging). Timepoint: start of treatment, 6th and 12th month. Method of measurement: Magnetic Resonance Imaging. | — |
Secondary
| Measure | Time frame |
|---|---|
| EDSS. Timepoint: Start of Treatment, 1st, 2nd, 3rd, 4th, 5th, 6th, 8th, 10th, and 12th month. Method of measurement: Asking from patients.;MSIS quality of life questionnaire. Timepoint: Start of Treatment, 1st, 2nd, 3rd, 4th, 5th, 6th, 8th, 10th, and 12th month. Method of measurement: Completing the questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Shahryar Nafisi
Shariati hospital, Tehran University of Medical Sciences, Tehran, Iran
Outcome results
None listed